Patients' Assessment of Satisfaction for Stroke Prevention in Atrial Fibrillation --- Impact of Conventional Oral Anticoagulant (OAC) Compared With Novel Oral Anticoagulant (NOAC) (PASSION)

Study summary

No information provided.

Study identification

• EU PAS number:
  EUPAS19558
• Study ID:
  28205
• Official title and acronym:
  Patients' Assessment of Satisfaction for Stroke Prevention in Atrial Fibrillation --- Impact of Conventional Oral Anticoagulant (OAC) Compared With Novel Oral Anticoagulant (NOAC) (PASSION)
• DARWIN EU® study:
  No
• Study countries:
  Taiwan
• Study description:
  To describe the treatment perception from patients with non-valvular atrial fibrillation (NVAF) receiving Pradaxa® or VKA for stroke prevention by using the self-estimation questionnaire of PACT-Q during a 6-month study period.
• Study status:
  Finalised

Study timelines

Date when funding contract was signed

Actual:19/06/2017

Study start date

Planned:19/06/2017

Actual:20/06/2017

Data analysis start date

Planned:30/06/2017

Actual:23/06/2017

Date of final study report

Planned:31/12/2019

Actual:27/06/2019

Sources of funding

Pharmaceutical company and other private sector 

More details on funding

Boehringer-Ingelheim

Regulatory

• Was the study required by a regulatory body?:
  No
• Is the study required by a Risk Management Plan (RMP)?:
  Not applicable

Other study registration identification numbers and links

1160-0286; NCT03187197